Results 141 to 150 of about 757,323 (338)

Retrospective Analysis of Familial Clustering for Malignant Melanoma

open access: yes, 2003
Background: Malignant Melanoma (MM) is familial in 5-7% of cases. Germline mutations of the CDKN2 and CDK4 genes are involved in the pathogenesis of hereditary MM, but the high frequency of familial clustering suggests other genes involved.
DELFINO, MARIO   +8 more
core  

Value of sono-elastography for detecting sentinel nodes in cutaneous malignant melanoma patients

open access: yes肿瘤影像学, 2015
   Objective: To evaluate the value of sono-elastography for detecting sentinel nodes in cutaneous malignant melanoma patients. Methods: Lymph nodes that were suspected to be sentinel nodes in cutaneous malignant melanoma patients were enrolled,
HUANG Junhua, SONG Shibo, CHEN Dan
doaj  

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

open access: yesAllergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz   +22 more
wiley   +1 more source

Sentinel Lymph Node Biopsy in Clinically Node‐Negative Merkel Cell Carcinoma: An Update of the Westmead Hospital Experience

open access: yesANZ Journal of Surgery, EarlyView.
ABSTRACT Background Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine malignancy with a high risk of nodal metastasis. Sentinel lymph node biopsy (SLNB) is used to stage clinically node‐negative disease and to guide adjuvant therapy decisions.
Julie Ahn   +2 more
wiley   +1 more source

Second primary cancers in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia—cumulative burden without generalized excess cancer risk

open access: yesBritish Journal of Haematology, EarlyView.
Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard   +2 more
wiley   +1 more source

Mortalidade por melanoma cutâneo no Brasil: análise de tendência de 1996 a 2006. [PDF]

open access: yes, 2010
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Zanatta, Débora
core  

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia   +6 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Melanoma maligno: Diagnóstico clínico x histopatológico nas especialidades médicas. [PDF]

open access: yes, 1998
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Departamento de Clínica Cirúrgica, Curso de Medicina, Florianópolis ...
Soares, Claúdia Bernadet
core  

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy